



VULCAN

VULCAN Overview

Healthcare delivery through augmented reality

Ramy Danial

Chief Financial Officer

Ramy.Danial@tienovix.com

www.tienovix.com

Q2 2020

Disclaimer

This Material: A VULCAN Investor Brief and any accompanying materials (collectively, the "Evaluation Material") have been prepared solely for informational purposes and are being supplied by or on behalf of Tienovix, LLC (together with its affiliates, "Tienovix") and/or one or more of its affiliates to you in your capacity as a prospective purchaser or investor (the "Recipient") in considering an acquisition or subscription of (or similar transaction involving) the equity interests described herein (the "Transaction").

ACCEPTANCE OF THE EVALUATION MATERIAL CONSTITUTES AN AGREEMENT TO BE BOUND BY THE TERMS OF THIS NOTICE. IF THE RECIPIENT IS NOT WILLING TO ACCEPT THE EVALUATION MATERIAL ON THE TERMS SET FORTH IN THIS NOTICE, IT MUST RETURN THE EVALUATION MATERIAL TO TIENOVIX IMMEDIATELY WITHOUT MAKING ANY COPIES THEREOF, EXTRACTS THEREFROM OR USE THEREOF.

The Recipient acknowledges and agrees that (i) the Evaluation Material is provided to the Recipient for informational purposes, (ii) none of Tienovix or any of its advisors or representatives bears any responsibility (or shall be liable) for the accuracy or completeness (or lack thereof) of any information contained within the Evaluation Material, (iii) no representation regarding the material within the Evaluation Material is made herein by Tienovix or its advisors or representatives, (iv) none of Tienovix or any of its advisors or representatives has made an independent verification as to the accuracy or completeness of the information within the Evaluation Material, and (v) none of Tienovix or any of its advisors or representatives shall have any obligation to update or supplement any information contained within the Evaluation Material or otherwise provide additional information. The Evaluation Material has been prepared to assist interested parties in making their own evaluation of the Transaction and does not purport to be all-inclusive or to contain all of the information that a prospective purchaser may consider material or desirable in making its decision to invest in the Transaction. Each Recipient of the information and data contained in the Evaluation Material should take such steps as it deems necessary to assure that it has the information it considers material or desirable in making any decision to transact and should perform its own independent investigation and analysis of the Transaction. The Recipient represents that it is sophisticated and experienced in investing in transactions similar to the Transaction. The information and data contained in the Evaluation Material should not be considered as a recommendation by Tienovix or any of its advisors or representatives that any Recipient enter into the Transaction.

The Recipient acknowledges that (a) Tienovix is not in the business of providing legal, tax, investment or accounting advice, (b) the Recipient understands that there may be legal, tax, investment or accounting risks associated with the Transaction, (c) the Recipient should receive legal, tax, investment and accounting advice from advisors with appropriate expertise to assess relevant risks, (d) the Recipient should apprise senior management in its organization as to the legal, tax, investment and accounting advice (and of applicable risks) associated with the Transaction and the disclaimers as to these matters, and (e) none of Tienovix or any of its advisors or representatives is making or will make any representation to any Recipient regarding the legality of an investment by any Recipient or any other person in the Transaction.

The Evaluation Material includes certain forward-looking statements and projections. Any such statements and projections reflect various estimates and assumptions by Tienovix concerning anticipated results. Whether or not any such forward-looking statements or projections are in fact achieved will depend upon future events which are uncertain and subject to a number of business and other risks. Accordingly, actual results may vary from the projected results and such variations may be material. Prospective investors should not rely on such forward-looking statements and projections.

It is understood that unless and until definitive agreements regarding the Transaction between the parties thereto have been executed, neither Tienovix nor the Recipient will be under no any legal obligation of any kind whatsoever with respect to the Transaction by virtue of the Evaluation Material except for any confidentiality agreement and, with respect to the Recipient, for the matters specifically agreed to herein. This Notice and any confidentiality agreement between Tienovix and Recipient together embody the entire understanding and agreement between the Recipient and Tienovix with respect to the information within the Evaluation Material and supersede all prior understandings and agreements relating thereto.

Tienovix reserves the right at any time, without prior notice to any Recipient of the Evaluation Material or any other party, to do any or all of the following in its sole and absolute discretion: (i) negotiate with one or more parties and to enter into a definitive agreement with respect to the Transaction, (ii) terminate further participation in the investigation and proposal process by any or all parties, (iii) request the return of the Evaluation Material, (iv) modify the structure of the Transaction, (v) modify any procedures relating to the investigation, proposal and negotiation process described herein, (vi) waive any irregularity in or the nonconformity in any respect of any proposal submitted by any party, and (vii) modify or waive any criteria or factors used to evaluate any proposal or to select the winning proposal.

THE EVALUATION MATERIAL DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITY. THE EVALUATION MATERIAL (OR ANY PART OF IT) MAY NOT BE REPRODUCED OR REDISTRIBUTED, PASSED ON, OR THE CONTENTS OTHERWISE DIVULGED, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED IN WHOLE OR IN PART FOR ANY PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF TIENOVIX. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS. THE EVALUATION MATERIAL IS NOT DIRECTED TO, OR INTENDED FOR DISTRIBUTION TO OR USE BY, ANY PERSON OR ENTITY THAT IS A CITIZEN OR RESIDENT OR LOCATED IN ANY LOCALITY, STATE, COUNTRY OR OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION, AVAILABILITY OR USE WOULD BE CONTRARY TO LAW OR REGULATION OR WHICH WOULD REQUIRE ANY REGISTRATION, APPROVAL OR LICENSING WITHIN SUCH JURISDICTION. THE TRANSACTION HAS NOT BEEN RECOMMENDED BY ANY PERSON, INCLUDING ANY U.S. FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THE EVALUATION MATERIAL.

About Us

Vulcan Devices, LLC

a Tienovix™ portfolio company

Tienovix™ was founded in 2019 by former NASA contractors to commercialize cutting edge technologies refined from NASA over the last 20 years. Utilizing the power of augmented reality, Tienovix™ has launched a multi-function software system for Microsoft's HoloLens 2 that transforms the device into a powerful learning tool that spans across multiple fields and industries from medical to oil and gas. With deep-machine learning and forward-leading procedural guidance, Tienovix™ aspires to cultivate a new wave of expert operators at a fraction of the time and resources it currently takes.



A \$7B Sonography Challenge Worth Solving

Sonography is the most common diagnostic imaging technology after x-ray. Healthcare providers embrace sonography across several critical applications, including:

- Anesthesiology
- Cardiology
- Gastroenterology
- Neonatology
- Orthopedics
- Pulmonology



However:

- 1) Healthcare providers face critical challenges as ultrasound demand increases due to new protocols as a result of COVID 19 and an aging population.
- 2) Certified and skilled sonographers are in short supply but are essential for accurate diagnoses and high-quality images.
- 3) Around 80% of sonographers suffer from Repetitive Strain Injuries due to poor delivery ergonomics.


The Solution

Apply Augmented Reality to revolutionize sonography through enhanced knowledge and real-time guidance.

Introducing **VULCAN LIVE-DISPLAY™** & **VULCAN-TRAINING™**



Performing More Ultrasounds Safely Through Augmented Reality



What is VULCAN™ ?

VULCAN™ is a suite of patented and proprietary human-machine interface systems that are capable of facilitating training, diagnostics, remote monitoring & analysis, and data acquisition & retention through augmented reality.

Powerful Display Unit

VULCAN™ allows a sonographer to view the ultrasound image produced by the underlying ultrasound device through a mixed reality device allowing the user to simultaneously see the patient while performing the ultrasound procedure.

Artificial Intelligence

The VULCAN™ Artificial Intelligence actively monitors and provides 3D overlay guidance to remove guesswork and ensure proper training allowing more ultrasound operators to be certified to meet the growing demand.

Remote Supervision

VULCAN™ features telemedicine solutions where a physician can supervise and analyze, in real-time, the results of the ultrasound from his/her computer screen while watching the user perform the ultrasound procedure.

Record and Review

VULCAN™ enables sonographers to record ultrasound images as video, enabling the physician to go back and review if necessary.

FDA Compliance

VULCAN™ is FDA registered as Class I, 510(k) exempt medical device (Registration # 3016544222) and currently in-process of filing a pre-submission for clinical use.

Market Transformation Rewards are Substantial

Medical diagnostic innovation is being enabled by technological advances in augment reality and artificial intelligence and accelerated by powerful social trends such increased demand of healthcare services from aging baby boomers.

+ \$45B

Medical Diagnostic Market

+ \$11B

Ultrasound Market

+ \$1B

Innovative Hospitals

Economics: Monetizing the Model



Integrated Systems
(Capitated/Bundled/FFS)
\$47B US Market

Systems Proposition


- Patient Outcomes, Cost containment
- Streamlines quality systems and training
- Establishes productivity and KPI measurement



Medical Imaging Accts.
(Acute, Stand Alone, Integrated)
\$19B US Market

Monetary Proposition

- Payback in less than 1 year of investment for account
- Produces on average 15 to 25% better productivity
- Creates greater patient capacity and throughput



Economic Buyers
(C-Suite-ACO)
\$18.8 B US Market

Operating Proposition

- Patient Outcomes, Cost Savings (Direct & Indirect)
- Established economic model for capital investment
- Creates measurable KPI's by service line

Note: Complete ROI Model can be customized per account

Current Partnership Opportunities



MGH/HST Athinoula A. Martinos
Center for Biomedical Imaging




CENTER FOR
DIAGNOSTIC IMAGING



Banner
University Medicine

Go-To-Market Strategy



We have laid the groundwork for an aggressive sales deployment targeting high impact use cases among our deep industry relationships.

Key Target Markets

- Innovation seeking hospitals
- Top tier ultrasound manufacturers

Geographic Priorities by MSA

- *Tier I:* Houston, Minneapolis, Boston, Phoenix
- *Tier II:* Los Angeles, New York, Cleveland

Primary Offerings

- VULCAN Live-Display™
- VULCAN-Training™
- VULCAN Scan-Assist™ (Q4 2020)
- VULCAN Automated-Diagnostics™ (Q4 2021)

Primary Channels

- Dedicated Distributors – Imaging
- Direct technical and customer support

Building a Strong & Sustainable Commercial Pipeline

Product Pipeline Timeline

VULCAN
Live-Display™



Available Now

VULCAN-
Training™



Available Now

VULCAN
Scan-Assist™



Expected Deployment
Q4 2020

VULCAN
Automated-
Diagnostics™



Expected Deployment
Q4 2021

VULCAN is Revolutionizing Sonography.

Join Us.



Contact Information:

Ramy Danial

ramy.danial@tienovix.com

www.tienovix.com